1h Free Analyst Time
Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Regeneron Pharmaceuticals Inc (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.Regeneron Pharmaceuticals Inc Key Recent Developments
- Mar 29, 2023: Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies
- Feb 03, 2023: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- Nov 18, 2022: Regeneron, CytomX partner to develop bispecific cancer therapies
- Nov 03, 2022: Regeneron presents new data at ASH from advancing hematology pipeline across multiple blood cancers and disorders
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Xbrane Biopharma AB
- Torii Pharmaceutical Co Ltd
- Teva Pharmaceutical Industries Ltd
- Stada Arzneimittel AG
- Sanofi
- Samsung Bioepis Co Ltd
- Pfizer Inc
- Novartis AG
- Merck & Co Inc
- Maruho Co Ltd
- LEO Pharma Inc
- Japan Tobacco Inc
- Incyte Corp
- GSK plc
- Gilead Sciences Inc
- Genentech USA Inc
- Galapagos NV
- Formycon AG
- Eli Lilly and Co
- Coherus BioSciences Inc
- Chugai Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Bristol-Myers Squibb Co
- Biogen Inc
- Bioeq IP AG
- Bayer AG
- Bausch + Lomb Corp
- AstraZeneca Plc
- Amgen Inc
- Allergan Inc
- Alimera Sciences Inc
- AbbVie Inc
- AstraZeneca Plc
- AbbVie Inc
- Alimera Sciences Inc
- Teva Pharmaceutical Industries Ltd
- Chugai Pharmaceutical Co Ltd
- LEO Pharma Inc
- GSK plc
- Bristol-Myers Squibb Co
- Incyte Corp
- Pfenex Inc
- Sanofi
- Allergan Inc
- Pfizer Inc
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Japan Tobacco Inc
- Gilead Sciences Inc
- Novartis AG
- Merck & Co Inc
- Genentech USA Inc
- Bayer AG
- Samsung Bioepis Co Ltd
- Amgen Inc
- Eli Lilly and Co